Search

Search Constraints

You searched for: Author/Creator Master, Viraj

Search Results

1. 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy. (9th November 2020)

2. 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy. (9th November 2020)

3. 255 Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies. (9th November 2020)

4. 44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). (10th December 2020)

5. 44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). (9th November 2020)

6. 45 Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI). (9th November 2020)

7. 637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). (10th December 2020)

8. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. (January 2019)

10. Elevated preoperative C‐reactive protein is associated with renal functional decline and non‐cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). (19th November 2020)